Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses
of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.
Phase:
Phase 3
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc. US WorldMeds LLC
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A rimabotulinumtoxinB